65
Participants
Start Date
July 18, 2018
Primary Completion Date
June 24, 2019
Study Completion Date
June 24, 2019
AK002
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
Placebo
Placebo
Icahn School of Medicine at Mount Sinai, New York
Care Access Research, Pottsville
University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia
National Institutes of Health, Bethesda
University of North Carolina - Chapel Hill, Chapel Hill
Riverside Clinical Research, Edgewater
Advanced Research Institute, New Port Richey
Vanderbilt University, Nashville
ClinSearch, Chattanooga
Cincinnati Children's Hospital, Cincinnati
Indiana University Health, Indianapolis
University of Iowa, Iowa City
Mayo Clinic, Rochester
Northwestern, Chicago
Avant Research Associates, Austin
UC Denver, Aurora
University of Utah, Salt Lake City
Phoenician Centers for Research and Innovation, Phoenix
Mayo Clinic, Scottsdale
Ventura Clinical Trials, Ventura
Tufts Medical Center, Boston
Lead Sponsor
Allakos Inc.
INDUSTRY